|
1
|
Lièvre A, Bachet JB, Le Corre D, Boige V,
Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Di Fiore F, Blanchard F, Charbonnier F, Le
Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech
JJ, et al: Clinical relevance of KRAS mutation detection in
metastatic colorectal cancer treated by Cetuximab plus
chemotherapy. Br J Cancer. 96:1166–1169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khambata-Ford S, Garrett CR, Meropol NJ,
Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin
AK, et al: Expression of epiregulin and amphiregulin and K-ras
mutation status predict disease control in metastatic colorectal
cancer patients treated with cetuximab. J Clin Oncol. 25:3230–3237.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Benvenuti S, Sartore-Bianchi A, Di
Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S and Bardelli
A: Oncogenic activation of the RAS/RAF signaling pathway impairs
the response of metastatic colorectal cancers to anti-epidermal
growth factor receptor antibody therapies. Cancer Res.
67:2643–2648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Nicolantonio F, Martini M, Molinari F,
Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S, et al: Wild-type BRAF is required for response
to panitumumab or cetuximab in metastatic colorectal cancer. J Clin
Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gibbs JBSI, Sigal IS, Poe M and Scolnick
EM: Intrinsic GTPase activity distinguishes normal and oncogenic
ras p21 molecules. Proc Natl Acad Sci USA. 81:5704–5708. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garnett MJ and Marais R: Guilty as
charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang GJ, Zhou H, Xiao HX, Li Y and Zhou
T: MiR-378 is an independent prognostic factor and inhibits cell
growth and invasion in colorectal cancer. BMC Cancer. 14:109–118.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mosakhani N, Sarhadi VK, Borze I,
Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P and
Knuutila S: MicroRNA profiling differentiates colorectal cancer
according to KRAS status. Genes Chromosomes Cancer. 51:1–9. 2012.
View Article : Google Scholar
|
|
12
|
Faltejskova P, Svoboda M, Srutova K,
Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K,
Kiss I, et al: Identification and functional screening of microRNAs
highly deregulated in colorectal cancer. J Cell Mol Med.
16:2655–2666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Ma B, Ji X, Deng Y, Zhang T, Zhang
X, Gao H, Sun H, Wu H, Chen X, et al: MicroRNA-378-5p suppresses
cell proliferation and induces apoptosis in colorectal cancer cells
by targeting BRAF. Cancer Cell Int. 15:402015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nagalingam RS, Sundaresan NR, Gupta MP,
Geenen DL, Solaro RJ and Gupta M: A cardiac-enriched microRNA,
miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J
Biol Chem. 288:11216–11232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Walczak R and Tontonoz P: Setting fat on
fire. Nat Med. 9:1348–1349. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Crunkhorn S, Dearie F, Mantzoros C, Gami
H, da Silva WS, Espinoza D, Faucette R, Barry K, Bianco AC and
Patti ME: Peroxisome proliferator activator receptor gamma
coactivator-1 expression is reduced in obesity: Potential
pathogenic role of saturated fatty acids and p38 mitogen-activated
protein kinase activation. J Biol Chem. 282:15439–15450. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gerin I, Bommer GT, McCoin CS, Sousa KM,
Krishnan V and MacDougald OA: Roles for miRNA-378/378* in adipocyte
gene expression and lipogenesis. Am J Physiol Endocrinol Metab.
299:198–206. 2010.
|
|
18
|
Carrer M, Liu N, Grueter CE, Williams AH,
Frisard MI, Hulver MW, Bassel-Duby R and Olson EN: Control of
mitochondrial metabolism and systemic energy homeostasis by
microRNAs 378 and 378. Proc Natl Acad Sci USA. 109:15330–15335.
2012. View Article : Google Scholar
|
|
19
|
Lin J, Yang R, Tarr PT, Wu PH, Handschin
C, Li S, Yang W, Pei L, Uldry M, Tontonoz P, et al: Hyperlipidemic
effects of dietary saturated fats mediated through PGC-1beta
coactivation of SREBP. Cell. 120:261–273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wilson PM and Lenz HJ: Integrating
biomarkers into clinical decision making for colorectal cancer.
Clin Colorectal Cancer. 9(Suppl 1): S16–S27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cushman-Vokoun AM, Stover DG, Zhao Z,
Koehler EA, Berlin JD and Vnencak-Jones CL: Clinical utility of
KRAS and BRAF mutations in a cohort of patients with colorectal
neoplasms submitted for microsatellite instability testing. Clin
Colorectal Cancer. 12:168–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dollah S, Abdulkarim SM, Ahmad SH,
Khoramnia A and Ghazali HM: Physicochemical properties and
potential food applications of Moringa oleifera seed oil blended
with other vegetable oils. J Oleo Sci. 63:811–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nelson VM and Benson AB III: Status of
targeted therapies in the adjuvant treatment of colon cancer. J
Gastrointest Oncol. 4:245–252. 2013.PubMed/NCBI
|
|
24
|
Yu J, Kong X, Liu J, Lv Y, Sheng Y, Lv S,
Di W, Wang C, Zhang F and Ding G: Expression profiling of
PPARγ-regulated microRNAs in human subcutaneous and visceral
adipogenesis in both genders. Endocrinology. 155:2155–2165. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feng M, Li Z, Aau M, Wong CH, Yang X and
Yu Q: Myc/miR-378/TOB2/cyclin D1 functional module regulates
oncogenic transformation. Oncogene. 30:2242–2251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kruszewski W, Kowara R, Rzepko R, Warezak
C, Zieliński J, Gryglewski G, Kopacz A, Jastrzebski T and Pawełczyk
T: K-RAS point mutation, and amplification of C-MYC and C-ERBB2 in
colon adenocarcinoma. Folia Histochem Cytobiol. 42:173–179.
2004.PubMed/NCBI
|
|
27
|
Chen LT, Xu SD, Xu H, Zhang JF, Ning JF
and Wang SF: MicroRNA-378 is associated with non-small cell lung
cancer brain metastasis by promoting cell migration, invasion and
tumor angiogenesis. Med Oncol. 29:1673–1680. 2012. View Article : Google Scholar
|
|
28
|
Deng H, Guo Y, Song H, Xiao B, Sun W, Liu
Z, Yu X, Xia T, Cui L and Guo J: MicroRNA-195 and microRNA-378
mediate tumor growth suppression by epigenetical regulation in
gastric cancer. Gene. 518:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eichner LJ, Perry MC, Dufour CR, Bertos N,
Park M, St-Pierre J and Giguère V: miR-378* mediates
metabolic shift in breast cancer cells via the PGC-1β/ERRγ
transcriptional pathway. Cell Metab. 12:352–361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee DY, Deng Z, Wang CH and Yang BB:
MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis
by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA.
104:20350–20355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li LH, Gao Q, Wang XY and Guo ZJ: miR-378
suppresses HBV-related hepatocellular carcinoma tumor growth by
directly targeting the insulin-like growth factor 1 receptor.
Zhonghua Gan Zang Bing Za Zhi. 21:609–613. 2013.In Chinese.
PubMed/NCBI
|
|
32
|
Scapoli L, Palmieri A, Lo Muzio L,
Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M and
Carinci F: MicroRNA expression profiling of oral carcinoma
identifies new markers of tumor progression. Int J Immunopathol
Pharmacol. 23:1229–1234. 2010.
|
|
33
|
Mensink RP, Zock PL, Kester AD and Katan
MB: Effects of dietary fatty acids and carbohydrates on the ratio
of serum total to HDL cholesterol and on serum lipids and
apolipoproteins: A meta-analysis of 60 controlled trials. Am J Clin
Nutr. 77:1146–1155. 2003.PubMed/NCBI
|
|
34
|
Zhao L, Hu Y, Xu D and Cai K: Surface
functionalization of titanium substrates with chitosan-lauric acid
conjugate to enhance osteoblasts functions and inhibit bacteria
adhesion. Colloids Surf B Biointerfaces. 119:115–125. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fauser JK, Matthews GM, Cummins AG and
Howarth GS: Induction of apoptosis by the medium-chain length fatty
acid lauric acid in colon cancer cells due to induction of
oxidative stress. Chemotherapy. 59:214–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
